From Yahoo Finance: 2025-06-23 01:34:00

UBS has reduced its price target on Regeneron Pharmaceuticals, Inc. (REGN) from $633 to $560, citing mixed corporate updates and recent pipeline advancements. The company faces short-term concerns due to weakening Eylea franchise. Recent strategic actions show expansion beyond ophthalmology, but market sentiment remains wary.

Despite long-term potential in pipeline updates, UBS believes pressure from existing franchises outweighs benefits. UBS maintains a Neutral rating on Regeneron Pharmaceuticals, Inc. (REGN). The company’s recent licensing agreements and acquisitions demonstrate growth, but Eylea franchise difficulties persist.

Regeneron Pharmaceuticals, Inc. (REGN) has seen recent developments such as the $256 million acquisition of 23andMe and licensing agreements. UBS acknowledges the company’s potential as an investment but suggests that certain AI stocks offer greater upside with less downside risk. Market sentiment remains cautious due to Eylea franchise challenges.

Read more: UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).